CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionIMC-Chicago, LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
IMC-Chicago, LLC ownership in CRSP / CRISPR Therapeutics AG

On November 4, 2025 - IMC-Chicago, LLC filed a 13F-HR form disclosing ownership of 0 shares of CRISPR Therapeutics AG (US:CRSP) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on July 22, 2025 disclosing 23,080 shares of CRISPR Therapeutics AG. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

IMC-Chicago, LLC has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 314,900 of underlying shares valued at $14,979,793 USD and put options representing 251,900 of underlying shares valued at $11,982,883 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-04 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -23,080 -100.00 0 -100.00
2025-07-22 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 23,080 -39,134 -62.90 1,123 -47.00 0.0005
2025-04-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 62,214 -24,255 -28.05 2,117 -37.79 0.0012
2025-01-27 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 86,469 86,469 3,403 0.0016
2024-07-15 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -36,722 -100.00 0 -100.00
2024-04-12 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 36,722 -1,495 -3.91 2,503 4.60 0.0015
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 38,217 6,914 22.09 2,392 68.45 0.0016
2023-10-12 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 31,303 15,640 99.85 1,421 61.55 0.0013
2023-07-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 15,663 1,731 12.42 879 39.52 0.0008
2023-04-24 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,932 -6,974 -33.36 630 -25.80 0.0007
2023-04-24 2022-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 20,906 20,906 850 0.0013
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,906 20,906 1 0.0000
2022-08-05 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -21,994 -100.00 0 -100.00
2022-04-19 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 21,994 -24,086 -52.27 1,381 -60.45 0.0014
2022-02-08 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 46,080 18,036 64.31 3,492 11.25 0.0029
2021-11-05 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,044 15,291 119.90 3,139 52.01 0.0033
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 12,753 -7,667 -37.55 2,065 -17.00 0.0025
2021-05-14 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,420 20,420 2,488 0.0036
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 314,900 -34.38 14,980 -40.48 n/a n/a n/a
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 479,900 21.31 25,166 -1.84 n/a n/a n/a
2025-11-04 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 395,600 -23.36 25,639 2.11 n/a n/a n/a
2025-07-22 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 516,200 120.22 25,108 214.78 n/a n/a n/a
2025-04-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 234,400 2.63 7,977 -11.27 n/a n/a n/a
2025-01-27 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 228,400 71.73 8,990 43.87 n/a n/a n/a
2024-10-25 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 133,000 -10.80 6,248 -22.40 n/a n/a n/a
2024-07-15 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 149,100 62.07 8,053 28.42 n/a n/a n/a
2024-04-12 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 92,000 -51.60 6,271 -47.31 n/a n/a n/a
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 190,100 20.78 11,900 66.57 n/a n/a n/a
2023-10-12 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 157,400 -6.09 7,144 -24.07 n/a n/a n/a
2023-07-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 167,600 -10.28 9,409 11.38 n/a n/a n/a
2023-04-24 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 186,800 12.26 8,449 24.90 n/a n/a n/a
2023-04-24 2022-12-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 166,400 -7.91 6,764 -42.72 n/a n/a n/a
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 166,400 7 n/a n/a n/a
2022-11-08 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 180,700 -13.75 11,809 -7.24 n/a n/a n/a
2022-08-05 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 209,500 71.30 12,731 65.83 n/a n/a n/a
2022-04-19 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 122,300 14.62 7,677 -5.06 n/a n/a n/a
2022-02-08 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 106,700 5.12 8,086 -28.83 n/a n/a n/a
2021-11-05 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 101,500 2.22 11,361 -29.33 n/a n/a n/a
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 99,300 1.33 16,076 34.63 n/a n/a n/a
2021-05-14 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 98,000 11,941 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 251,900 27.22 11,983 15.40 n/a n/a n/a
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 198,000 -25.76 10,383 -39.93 n/a n/a n/a
2025-11-04 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 266,700 -13.83 17,285 14.81 n/a n/a n/a
2025-07-22 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 309,500 83.14 15,054 161.76 n/a n/a n/a
2025-04-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 169,000 5.10 5,751 -9.13 n/a n/a n/a
2025-01-27 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 160,800 79.06 6,329 50.05 n/a n/a n/a
2024-10-25 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 89,800 14.39 4,219 -0.50 n/a n/a n/a
2024-07-15 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 78,500 -26.98 4,240 -42.15 n/a n/a n/a
2024-04-12 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 107,500 -20.25 7,327 -13.17 n/a n/a n/a
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 134,800 40.71 8,438 94.07 n/a n/a n/a
2023-10-12 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 95,800 -14.77 4,348 -31.09 n/a n/a n/a
2023-07-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 112,400 27.58 6,310 58.38 n/a n/a n/a
2023-04-24 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 88,100 36.17 3,985 51.48 n/a n/a n/a
2023-04-24 2022-12-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 64,700 -27.14 2,630 -54.68 n/a n/a n/a
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 64,700 3 n/a n/a n/a
2022-11-08 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 88,800 -23.05 5,803 -17.25 n/a n/a n/a
2022-08-05 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 115,400 26.26 7,013 22.24 n/a n/a n/a
2022-04-19 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 91,400 -17.21 5,737 -31.42 n/a n/a n/a
2022-02-08 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 110,400 23.63 8,366 -16.30 n/a n/a n/a
2021-11-05 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 89,300 0.56 9,995 -30.47 n/a n/a n/a
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 88,800 11.70 14,376 48.41 n/a n/a n/a
2021-05-14 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 79,500 9,687 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.